2024/25年中期流感疫苗有效性：8项欧洲研究，2024年9月至2025年1月

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2025-02-01 DOI:10.2807/1560-7917.ES.2025.30.7.2500102

Angela Mc Rose, Héloïse Lucaccioni, Kimberly Marsh, Freja Kirsebom, Heather Whitaker, Hanne-Dorthe Emborg, Amanda Bolt Botnen, Mark G O'Doherty, Francisco Pozo, Safraj Shahul Hameed, Nick Andrews, Mark Hamilton, Ramona Trebbien, Karina Lauenborg Møller, Diogo Fp Marques, Siobhan Murphy, Ross McQueenie, Jamie Lopez-Bernal, Simon Cottrell, Magda Bucholc, Esther Kissling

{"title":"2024/25年中期流感疫苗有效性：8项欧洲研究，2024年9月至2025年1月","authors":"Angela Mc Rose, Héloïse Lucaccioni, Kimberly Marsh, Freja Kirsebom, Heather Whitaker, Hanne-Dorthe Emborg, Amanda Bolt Botnen, Mark G O'Doherty, Francisco Pozo, Safraj Shahul Hameed, Nick Andrews, Mark Hamilton, Ramona Trebbien, Karina Lauenborg Møller, Diogo Fp Marques, Siobhan Murphy, Ross McQueenie, Jamie Lopez-Bernal, Simon Cottrell, Magda Bucholc, Esther Kissling","doi":"10.2807/1560-7917.ES.2025.30.7.2500102","DOIUrl":null,"url":null,"abstract":"The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 7","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843620/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.\",\"authors\":\"Angela Mc Rose, Héloïse Lucaccioni, Kimberly Marsh, Freja Kirsebom, Heather Whitaker, Hanne-Dorthe Emborg, Amanda Bolt Botnen, Mark G O'Doherty, Francisco Pozo, Safraj Shahul Hameed, Nick Andrews, Mark Hamilton, Ramona Trebbien, Karina Lauenborg Møller, Diogo Fp Marques, Siobhan Murphy, Ross McQueenie, Jamie Lopez-Bernal, Simon Cottrell, Magda Bucholc, Esther Kissling\",\"doi\":\"10.2807/1560-7917.ES.2025.30.7.2500102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 7\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843620/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

欧洲目前的2024/25流感季节特点是甲型H1N1流感pdm09、甲型H3N2和B/维多利亚病毒共循环，其中甲型H1N1流感pdm09占主导地位。来自8项欧洲研究（17个国家）的中期疫苗有效性（VE）估计表明，初级保健机构的全年龄甲型流感VE为32-53%，医院机构的全年龄甲型流感VE为33-56%，有一些信号表明，按亚型分类的VE较低，而对乙型流感的VE较高（各机构≥ 58%）。在可行的情况下，应鼓励接种流感疫苗，并加强其他预防措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.

The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.